GlaxoSmithKline and Five Prime ditch lung cancer ambitions as rivals pile in

Damian Garde

Partners and Therapeutics are abandoning their hopes of developing an early-stage drug for , pivoting to mesothelioma as the landscape gets more and more competitive.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS